Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 7/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20573263 | 0.84 | TUBB4A (0.47) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31448682 | 0.81 | FABP3 (0.49) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17797024 | 0.81 | CNR2 (0.44) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL17797004 | 0.79 | MAOA (0.44) | BRD4 | |
| SCHEMBL20573260 | 0.79 | SELL (0.43) | FYNLRRK2 | |
| SCHEMBL3131548 | 0.78 | BAZ2B (0.46) | FYN | |
| SCHEMBL274364 | 0.78 | FABP3 (0.53) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20573269 | 0.78 | TUBB4A (0.44) | — | |
| SCHEMBL17796936 | 0.78 | RORB (0.47) | — | |
| SCHEMBL29728528 | 0.78 | KMT2A (0.46) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | CCR3, CCR5, CCR1 | FYN 2332/4885BCHE 1451/4885ACHE 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.